MEDICATION-ASSISTED TREATMENT CENTERS OF EXCELLENCE

May 20, 2022 BIWEEKLY NEWSLETTER Vol. 49



COMPARATIVE EFFECTIVENESS ASSOCIATED WITH BUPRENORPHINE AND NALTREXONE IN OPIOID USE DISORDER AND CO-OCCURRING POLYSUBSTANCE USE

The goal of this observational comparative effectiveness study was to compare buprenorphine and naltrexone initiation among individuals with OUD with vs without co-occurring SUD and to assess the comparative effectiveness associated with buprenorphine and naltrexone against drug-related poisonings. Amongst over 47k individuals with co-occurring SUDs, there was decreased odds of receiving buprenorphine treatment but increased odds of initiating naltrexone. The findings suggest that individuals with polysubstance use were less likely to have either buprenorphine initiated and naltrexone than individuals without polysubstance use. Among individuals initiating MOUD, polysubstance use was associated with decreased buprenorphine and increased naltrexone initiation, despite buprenorphine's benefits in being a partial opioid agonist, providing opioid blockade and reducing overdose deaths.

WHAT'S INSIDE

UPCOMING EVENTS

5/25: MAT Lunch Hour: Addressing Cannabis Use

6/3: ECHO: SUD Initial & Follow-Up Assessments

6/10: ECHO: Place in Therapy for Injectable Buprenorphine

6/16: OBAT Navigator Skills Lab

HEADLINES

Stigma Around OUD & Challenges to Treatment

Assessment of Community-Level Vulnerability and Access to MOUD

County-level Sociodemographic Differences in Availability of 2 Medications for OUD

NJ Human Services Awards Additional Contracts to Help Treat Co-Occurring SUD

RESOURCES

Patient Health Communication Series

UPCOMING EVENTS



MAT LUNCH HOUR: ADDRESSING CANNABIS USE

WEDNESDAY, MAY 25TH FROM 12:00-1:00 PM

Co-hosted with the Camden Coalition, the MAT Lunch Hours are hour-long virtual meetings to hear from experts and discuss the latest in clinical and non-clinical issues affecting the MAT patient population.

OBAT NAVIGATOR MONTHLY RESOURCE CALLS & SKILLS LAB

THURSDAY, JUNE 16TH FROM 12:00-1:00 PM

The Camden Coalition is offering monthly resources calls & skills labs to provide ongoing opportunity for OBAT navigators & other SUD navigators/case managers to continue learning through:

- Hour-long deep dive of particular content areas
- Discussion of (de-identified) patient cases & support thinking through patient engagement strategies, potential resources, & how to practice self-care while doing this work
- Presentations & sharing updated resources about relevant topics

These events take place every 3rd Thursday of the month from 12pm - 1pm

UPCOMING PROJECT ECHOS

PROJECT ECHO IS STRAIGHT-FORWARD, SPECIFIC AND APPLICABLE. AT EVERY LIVE SESSION WE EXPLORE ACTIVE PATIENT CHALLENGES FROM MULTIPLE PERSPECTIVES. WE EACH HOLD A PIECE OF THE PUZZLE AND EVERYONE IS WELCOME TO SHARE EXPERIENCES. YOU'LL MEET PRACTITIONERS FROM ACROSS THE STATE THROUGH A SIMPLE VIDEO INTERFACE AND BECOME PART OF A COLLEGIAL COMMUNITY. YOU'LL HAVE A COMFORTABLE PLACE TO RETURN AND WILL BUILD ON WHAT YOU'RE LEARNING, MONTH TO MONTH.

SUD CQI PROJECT ECHO: INITIAL AND FOLLOW-UP ASSESSMENTS FOR THE SUD ENCOUNTER

FRIDAY, JUNE 3RD FROM 12:00-1:00 PM

This SUD session will discuss how to manage your patient's injectable buprenorphine while in therapy.

SUD MAT PROJECT ECHO: PLACE IN THERAPY FOR INJECTABLE BUPRENORPHINE

FRIDAY, JUNE 10TH FROM 12:00-1:00 PM

This SUD continuous quality improvement session will discuss how to measure treatment goals for your patients.

RECENT LITERATURE



PANEL DISCUSSION: STIGMA AROUND OPIOID USE DISORDER PRESENTS CHALLENGES TO TREATMENT

The following is written by Elinor Haider, the director of the Philadelphia Research and Policy initiative, discussing this panel discussion. Our Southern COE physician, Dr. Rachel Haroz, is featured!

The number of fatal drug overdoses in Philadelphia has been growing in recent years, with about 1,215 deaths in both 2017 and 2020. As fatalities have continued to rise, the focus has intensified on MOUD; the FDA has approved three drugs—methadone, naloxone, and buprenorphine—to treat OUD. The Pew Charitable Trusts hosted a couple of gatherings with experts to help frame the issues around the use of MOUD. The first meeting in May included health system leaders in the Philadelphia region to discuss new opportunities and looming challenges around using MOUD, especially buprenorphine. One of the main themes that emerged was the role that stigma plays in creating barriers to providing—and accessing—this lifesaving treatment. December's panel further explored insights into the barriers that stigma presents as well as opportunities to help overcome them. Panelists included Nicole O'Donnell, Rachel Haroz, and Hector Colon-Rivera. The event explored several key issues, such as the stigma surrounding OUD being pervasive throughout the health care system—including among health care providers, stigma extending beyond those providing medical treatment to include other systems that patients rely on, stigma discouraging people seeking OUD treatment—which can have grave consequences, and systemic stigma creating barriers for providers treating OUD. Panelists discussed all of the challenges to treatment that patients face due to stigma, and some opportunities to overcome these challenges.

Click here to watch the full video.


ASSESSMENT OF COMMUNITY-LEVEL VULNERABILITY AND ACCESS TO MEDICATIONS FOR OPIOID USE DISORDER

This cross-sectional study aimed to find whether the association of community vulnerability to disasters and pandemics with access to medications for opioid use disorder vary across urban and rural communities. It found that communities with greater social vulnerability did not have greater geographic access to medications, and the mismatch was greatest in suburban communities. Rural communities had poor geographic access regardless of vulnerability. This data suggests that disaster preparedness planning should include anticipation of access to MOUD and better match the location of services to communities with greater vulnerability to prevent inequities in opioid overdose deaths.

RECENT LITERATURE (CONT.)

COUNTY-LEVEL SOCIODEMOGRAPHIC DIFFERENCES IN AVAILABILITY OF TWO MEDICATIONS FOR OPIOID USE DISORDER


Factors that may influence MOUD availability include sociodemographic characteristics of which this study further explored. County-level DEA data were used to determine the presence or absence of buprenorphine treatment or opioid treatment programs and the level of availability of these types of treatment in a county. The study found that odds of a county having OTP availability were higher for counties with higher percentages of non-Hispanic Black and Hispanic populations and higher drug overdose death rates. Counties with higher percentages of persons in poverty and drug overdose death rates had higher odds of maximum potential buprenorphine treatment capacity, whereas counties with more people without health insurance, with disability, and rural counties had lower odds. Therefore, these findings show that socioeconomic differences have a big impact on accessing treatment and highlight the inequities involved.



NJ HUMAN SERVICES AWARDS ADDITIONAL CONTRACTS TO HELP PROVIDERS TREAT INDIVIDUALS WITH CO-OCCURRING SUBSTANCE USE DISORDER

Human Services Commissioner Sarah Adelman announced the Department has awarded additional contracts to help mental health and substance use disorder programs provide medication that can support addiction recovery. The $150,000 program will be supported through federal Substance Abuse and Mental Health Services Administration's State Opioid Response grant funding. Services are expected to start at the end of May. Funds will be used to ensure providers develop the ability to prescribe and dispense substance use disorder medications buprenorphine, naloxone and naltrexone, methadone and acamprosate. This includes recruiting additional medical staff and purchasing medical equipment. The contracts were awarded to New Hope Integrated Behavioral Healthcare and Maryville Addiction Treatment Center. Each provider received a $75,000 award. Recently, Human Services has also worked to expand mental health intervention programs in all 21 counties; awarded grants to create additional recovery centers to support individuals with substance use disorder, which are available in 19 counties; and awarded a contract to provide cultural competency training for opioid treatment providers to reduce the treatment gap experienced by Black residents.

RESOURCES



PATIENT HEALTH COMMUNICATION SERIES: SPECIFIC SUBSTANCES

We are excited to share our patient health communication series on specific substances including opioids, cannabis and marijuana, benzodiazepines, stimulants, and psychedelics, covering risks, signs and symptoms of use disorder, our Southern NJ MAT Center of Excellence clinical practice locations, and resources for patients and loved ones including our fentanyl test strips infographic, linkage to our interactive and printable statewide naloxone distribution and training programs guide, NARCAN® nasal spray administration infographic, and New Jersey Syringe Access Program and Safe Syringe Disposal guides. Download the materials, intended for practice implementation in emergency medicine and urgent care, primary care, behavioral health, and other preventative care settings. Additional materials as part of the series and on related topics will be made available on snjmatcoe.org.

Special thanks to our Southern NJ MAT Center of Excellence physician leaders, Kaitlan Baston, MD, DFASAM, Richard Jermyn, DO, FAAPMR, and Rachel Haroz, MD, FAACT; our pharmacist, Valerie Ganetsky, PharmD, BCPS; and our content manager, Patricia Fortunato. To request the forms in dot phrase templates, please contact Patricia at fortunato-patricia@cooperhealth.edu. To learn about our clinical mentorship opportunities with our multidisciplinary team and community-based collaboratives in Southern New Jersey, please contact southernnjcoe@rowan.edu.

MEDICATION-ASSISTED TREATMENT
CENTERS OF EXCELLENCE

24/7 MAT Provider Hotline: 844-HELP OUD (844-435-7683)

Northern NJ MAT COE Website & Email
Southern NJ MAT COE Website & Email